首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1865614

生物蛋白药物市场报告：趋势、预测与竞争分析（至2031年）

Bio-Protein Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2025年11月10日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录图表

全球生物蛋白药物市场前景广阔，製药和生物技术公司、合约研究机构 (CRO) 以及学术界都蕴藏着巨大的机会。预计2025年至2031年，全球生物蛋白药物市场将以8.9%的复合年增长率成长。推动该市场成长的关键因素包括：对标靶治疗的需求不断增长，从而促进了生物蛋白药物的发展；以及生物技术的进步，从而推动了创新生物蛋白药物的研发。

根据 Lucintel 的预测，单株抗体在预测期内有望实现高速成长。
从应用领域来看，製药和生物技术公司预计将经历更高的成长。
从区域来看，预计亚太地区在预测期内将达到最高的成长率。

生物蛋白製药市场的新趋势

生物蛋白製药市场正经历着变革，一些关键的新兴趋势正在重塑其格局。这些趋势包括生物相似药的创新、个人化医疗的兴起以及先进技术在药物研发中的应用。随着对生物製药需求的不断增长，这些趋势有望推动市场成长，改善患者疗效，并显着降低医疗成本。

生物相似药的成长：市场对生物相似药的需求日益增长，因为它们为昂贵的生物製药提供了更经济实惠的替代方案。包括FDA和EMA在内的全球监管机构正在简化生物相似药的核准流程，以促进其应用。随着更多生物相似药进入市场，竞争预计将降低价格，使更多患者能够获得治疗。
个人化医疗：个人化医疗根据基因谱客製化治疗方案，在生物蛋白製药市场正日益受到关注。这种方法能够实现更有效、更具针对性的治疗，尤其是在肿瘤和自体免疫疾病领域。精准医疗的出现正在革新患者照护，在改善治疗效果的同时，最大限度地减少传统治疗方法带来的副作用。
药物研发领域的技术创新：人工智慧 (AI) 和机器学习 (ML) 在药物研发中的应用正在改变生物蛋白製药市场。这些技术有助于识别潜在的治疗标靶、优化药物设计并预测患者反应，从而加速新型生物製药的开发并提高临床试验的效率。
新兴市场扩张：在印度和中国等慢性病盛行率不断上升的新兴市场，生物蛋白药物的应用日益广泛。经济实惠的生物相似药和本地化生产的增加正在改善这些地区生物製药的可及性。预计这些市场中产阶级的壮大和医疗改革将显着推动对生物蛋白药物的需求。
合作与策略联盟：製药公司正日益与生技公司和研究机构合作，共同开发创新生物蛋白药物。这些合作使公司能够获得新技术，分担研发成本，并加速新型生物製药的商业化。策略联盟正成为在生物蛋白药物市场保持竞争优势的关键因素。

生物相似药的成长、个人化医疗、人工智慧药物研发以及策略合作等新兴趋势正在重塑生物蛋白製药市场。这些发展提高了生物製药的可近性，改善了患者的治疗效果，并提升了药物研发的效率，为製药业更具创新性和永续的未来铺平了道路。

生物蛋白药物市场的最新趋势

生物蛋白药物市场近期的发展趋势反映出先进生物疗法的日益普及，以及降低治疗成本和提高治疗可及性的迫切需求。重大技术创新和监管变革正在推动生物蛋白药物在包括肿瘤、自体免疫疾病和代谢紊乱等多个治疗领域的研发和商业化进程。

FDA核准新型单株抗体：FDA核准新型单株抗体标誌着癌症免疫疗法取得了重大进展。这些生物製药已显示出治疗多种癌症（包括淋巴瘤和黑色素瘤）的疗效，也是肿瘤免疫疗法选择不断扩展这一更广泛趋势的一部分。与传统化疗相比，这些核准为副作用较少的创新治疗方法铺平了道路。
基因和细胞疗法的进展：基因和细胞疗法在生物蛋白质製药市场日益受到关注，尤其是在罕见遗传疾病和癌症的治疗领域。近期的突破性进展，例如基于 CRISPR 的疗法和 CAR-T 细胞疗法，已展现出令人鼓舞的成果。这些疗法有望从基因层面治癒疾病，使其成为治疗传统上难以治癒疾病的极具创新性的治疗方法。
生物相似药市场扩张：生物相似药市场持续扩张，越来越多的生物相似药进入肿瘤、风湿病和糖尿病等治疗领域。这些产品为品牌生物製药提供了更实惠的替代方案，这在新兴市场尤其重要。生物相似药的持续核准和广泛应用，使得生物蛋白药物更容易取得。
对生物技术Start-Ups的投资：对生物技术Start-Ups的大量投资正在推动新型生物蛋白药物的研发。创业投资和政府津贴正在支持生物製药，尤其是在个人化医疗和罕见疾病等领域。这些投资正在加速新型治疗方法的开发，并有助于扩大生物蛋白药物的研发管线。
监管变革与加速核准：全球监管机构正在简化生物蛋白药物（尤其是生物相似药和基因疗法）的核准流程。在美国和欧洲，已推出相关倡议，旨在加快新生物製药的审查，缩短其上市时间。这一趋势有望促进患者更快获得救命疗法，并加剧市场竞争。

生物蛋白药物市场的最新进展，包括FDA核准新型单株抗体、基因和细胞疗法的兴起以及生物相似药的扩张，正在改变治疗模式。这些进步推动了创新，提高了治疗的可及性，并加速了针对多种疾病的最先进治疗的研发。

The future of the global bio-protein drug market looks promising with opportunities in the pharma and biotech companies, cros, and academics markets. The global bio-protein drug market is expected to grow with a CAGR of 8.9% from 2025 to 2031. The major drivers for this market are the increasing demand for targeted therapies drives growth in bio-protein drugs. and the advancements in biotechnology enable the development of innovative bio-protein drugs.

Lucintel forecasts that, within the type category, monoclonal antibodies is expected to witness higher growth over the forecast period.
Within the application category, pharma and biotech companies is expected to witness the higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Bio-Protein Drug Market

The bio-protein drug market is evolving with key emerging trends that are reshaping its landscape. These trends include innovations in biosimilars, the rise of personalized medicine, and the integration of advanced technologies in drug discovery. As demand for biologics increases, these trends are expected to drive market growth, improve patient outcomes, and reduce healthcare costs ly.

Growth of Biosimilars: The demand for biosimilars is increasing as they offer a more affordable alternative to expensive biologic drugs. Regulatory agencies around the world, including the FDA and EMA, have streamlined approval processes for biosimilars, promoting their use. As more biosimilars enter the market, competition is expected to reduce prices and make treatments more accessible to patients ly.
Personalized Medicine: Personalized medicine, which tailors treatments based on genetic profiles, is gaining traction in the bio-protein drug market. This approach allows for more effective and targeted therapies, particularly in oncology and autoimmune diseases. The ability to deliver precision treatments is revolutionizing patient care, improving outcomes, and minimizing side effects associated with conventional therapies.
Technological Advancements in Drug Discovery: The integration of artificial intelligence (AI) and machine learning (ML) in drug discovery is transforming the bio-protein drug market. These technologies help in identifying potential therapeutic targets, optimizing drug design, and predicting patient responses. This is accelerating the development of new biologics and improving the efficiency of clinical trials.
Expansion in Emerging Markets: Bio-protein drugs are increasingly being adopted in emerging markets, such as India and China, where there is a rising prevalence of chronic diseases. Cost-effective biosimilars and increased local production are making biologics more accessible in these regions. The growing middle class and healthcare reforms in these markets are expected to drive significant demand for bio-protein drugs.
Collaboration and Strategic Partnerships: Pharmaceutical companies are increasingly forming partnerships with biotech firms and research institutions to co-develop innovative bio-protein drugs. These collaborations help companies to access new technologies, share research costs, and accelerate the commercialization of novel biologics. Strategic alliances are becoming a critical factor in staying competitive in the bio-protein drug market.

Emerging trends such as the growth of biosimilars, personalized medicine, AI-driven drug discovery, and strategic collaborations are reshaping the bio-protein drug market. These developments are making biologics more accessible, improving patient outcomes, and enhancing the efficiency of drug development, paving the way for a more innovative and sustainable future in the pharmaceutical industry.

Recent Developments in the Bio-Protein Drug Market

Recent developments in the bio-protein drug market reflect the increasing adoption of advanced biologic therapies and a focus on making treatments more affordable and accessible. Key innovations and regulatory changes are driving progress in the development and commercialization of bio-protein drugs across various therapeutic areas, including oncology, autoimmune diseases, and metabolic disorders.

FDA Approval of New Monoclonal Antibodies: The approval of new monoclonal antibodies by the FDA has led to significant advancements in cancer immunotherapy. These biologics have shown efficacy in treating various cancers, including lymphoma and melanoma, and are part of a broader trend of expanding immunotherapy options in oncology. These approvals are paving the way for innovative treatments with fewer side effects compared to traditional chemotherapy.
Advances in Gene and Cell Therapies: Gene and cell therapies are gaining traction in the bio-protein drug market, particularly in treating rare genetic disorders and cancers. Recent breakthroughs, such as CRISPR-based therapies and CAR-T cell treatments, are offering promising results. These therapies hold the potential to cure diseases at the genetic level, making them highly innovative in the treatment of previously untreatable conditions.
Expansion of Biosimilars: The biosimilar market is expanding, with an increasing number of biosimilars entering the market across therapeutic areas such as oncology, rheumatology, and diabetes. These products are offering more affordable alternatives to branded biologics, which is especially important in emerging markets. The continued approval and uptake of biosimilars are making bio-protein drugs more accessible ly.
Investment in Biotech Startups: Significant investment in biotech startups is driving the development of new bio-protein drugs. Venture capital and government grants are supporting innovation in biologics, particularly in areas such as personalized medicine and rare diseases. These investments are helping to accelerate the development of novel therapies and expand the pipeline of bio-protein drugs.
Regulatory Changes and Faster Approvals: Regulatory bodies worldwide are streamlining the approval process for bio-protein drugs, particularly biosimilars and gene therapies. In the U.S. and Europe, initiatives have been introduced to speed up the review of novel biologics, reducing time to market. This trend is expected to facilitate faster access to life-saving therapies and encourage greater competition in the market.

Recent developments in the bio-protein drug market, such as FDA approvals for new monoclonal antibodies, the rise of gene and cell therapies, and the expansion of biosimilars, are transforming the treatment landscape. These advancements are driving innovation, making therapies more accessible, and accelerating the development of cutting-edge treatments for a wide range of diseases.

Strategic Growth Opportunities in the Bio-Protein Drug Market

The bio-protein drug market offers numerous growth opportunities, driven by increasing demand for biologics, advancements in biotechnology, and a focus on improving patient outcomes. Companies are capitalizing on these opportunities to develop innovative treatments for chronic and rare diseases while expanding into emerging markets.

Oncology Treatments: The increasing demand for personalized cancer therapies presents a significant growth opportunity. Bio-protein drugs, including monoclonal antibodies and immune checkpoint inhibitors, are revolutionizing cancer treatment by offering more targeted and effective options. Continued investment in research and clinical trials for cancer therapies is expected to fuel the market's growth in oncology.
Rheumatology and Autoimmune Diseases: Bio-protein drugs are seeing increasing adoption in treating autoimmune disorders such as rheumatoid arthritis, lupus, and psoriasis. The development of biologics like tumor necrosis factor (TNF) inhibitors and interleukin inhibitors is improving treatment outcomes. The growing prevalence of autoimmune diseases ly offers substantial opportunities for growth in this therapeutic area.
Metabolic Disorders: Bio-protein drugs are becoming key treatments for metabolic disorders such as diabetes and obesity. Insulin analogs and growth hormone therapies are just a few examples of biologics being used to manage these conditions. As the prevalence of diabetes rises, there is a significant opportunity for bio-protein drugs to address this growing health challenge.
Gene and Cell Therapy Innovations: Gene and cell therapies are a major area of growth, particularly for rare genetic diseases. The success of CAR-T cell therapies and gene editing technologies like CRISPR is driving the market. Companies investing in these therapies are positioned to capitalize on unmet medical needs and offer potential cures for conditions that were previously difficult or impossible to treat.
Expansion in Emerging Markets: The growing middle class and healthcare reforms in emerging markets, such as China and India, offer a significant opportunity for the bio-protein drug market. With increased access to healthcare and a rising prevalence of chronic diseases, these regions are expected to see a surge in demand for biologics, including biosimilars.

Strategic growth opportunities in oncology, rheumatology, metabolic disorders, gene therapy, and emerging markets are reshaping the bio-protein drug landscape. These areas offer significant potential for market expansion, innovation, and addressing unmet medical needs, driving continued growth in the bio-protein drug market.

Bio-Protein Drug Market Driver and Challenges

The bio-protein drug market is influenced by various drivers and challenges, including technological advancements, economic factors, and regulatory hurdles. Understanding these drivers and challenges is crucial for stakeholders to navigate the complex landscape and capitalize on growth opportunities.

The factors responsible for driving the Bio-protein Drug market include:

1. Technological Advancements: Advancements in biotechnology, such as gene editing, protein engineering, and monoclonal antibody development, are driving the growth of the bio-protein drug market. These innovations are leading to the development of more effective and targeted treatments, improving patient outcomes.

2. Rising Demand for Personalized Medicine: As healthcare moves toward personalized medicine, bio-protein drugs are becoming key in providing tailored treatments. Genetic profiling and biomarker-based therapies are enabling more precise and effective treatments, fueling the demand for biologics.

3. Aging Population: The growing aging population is driving the demand for bio-protein drugs, particularly in the treatment of chronic conditions like cancer, diabetes, and autoimmune diseases. Older adults are more likely to require long-term biologic therapies, expanding market opportunities.

4. Regulatory Support for Biologics: Regulatory bodies are providing faster approval pathways for biologics, including biosimilars and gene therapies. This is helping to accelerate the development and availability of bio-protein drugs, increasing their adoption ly.

5. Increasing Prevalence of Chronic Diseases: The rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, is creating a strong demand for bio-protein drugs. These conditions require long-term treatment, creating a sustained need for biologics.

Challenges in the Bio-protein Drug market are:

1. High Production Costs: The high production costs of bio-protein drugs, especially biologics like monoclonal antibodies and gene therapies, pose a significant challenge. These costs can limit access to treatments, particularly in low-income regions, and put pressure on healthcare systems.

2. Regulatory Hurdles: While regulatory bodies have made strides in approving biologics, navigating complex regulations in different markets remains a challenge for companies. Variations in approval processes across regions can delay market entry and increase development costs.

3. Intellectual Property Issues: Patent expirations and intellectual property disputes over biosimilars and innovative biologics can create legal barriers. Companies need to protect their innovations while also addressing the growing competition from biosimilars.

Technological advancements, demand for personalized medicine, and increasing chronic disease prevalence are key drivers of the bio-protein drug market. However, challenges such as high production costs, regulatory hurdles, and intellectual property issues need to be addressed for sustained growth and market expansion.

List of Bio-Protein Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bio-protein drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bio-protein drug companies profiled in this report include-

Abbott Laboratories
Bayer AG
Eli Lilly and Company
Amgen Inc.
Biocon Ltd.
Dr. Reddy'S Laboratories
Roche

Bio-Protein Drug Market by Segment

The study includes a forecast for the global bio-protein drug market by type, application, and region.

Bio-Protein Drug Market by Type [Value from 2018 to 2031]:

Monoclonal Antibodies
Therapeutic Proteins
Vaccines

Bio-Protein Drug Market by Application [Value from 2018 to 2031]:

Pharma And Biotech Companies
Cros
Academics

Bio-Protein Drug Market by Region [Value from 2018 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Bio-Protein Drug Market

The bio-protein drug market is experiencing rapid growth due to advancements in biotechnology, increased demand for personalized medicine, and the rising prevalence of chronic diseases. Bio-protein drugs, which include monoclonal antibodies, enzymes, and hormones, are revolutionizing treatments in areas such as cancer, autoimmune disorders, and diabetes. The United States, China, Germany, India, and Japan are leading regions, each showing distinct developments and trends that are shaping the future of this dynamic market.

United States: In the United States, the bio-protein drug market continues to grow, driven by advancements in immunotherapy, targeted treatments, and biosimilars. The Food and Drug Administration (FDA) has approved several new monoclonal antibodies and gene therapies, particularly for cancer and autoimmune diseases. Companies are focusing on developing personalized treatments tailored to genetic profiles. The increasing demand for biologics in the aging population and investments in biotech startups are fueling continued growth in this sector.
China: China is emerging as a leader in the bio-protein drug market due to its rapid advancements in biotechnology and favorable regulatory reforms. The Chinese government has introduced policies that support research and development, and several homegrown biotech companies are making significant strides in developing biosimilars and monoclonal antibodies. With an increasing demand for biologics driven by rising chronic disease rates, China is poised to be a key player in the bio-protein drug market.
Germany: Germany is a major hub for bio-protein drug development, with strong investments in research and manufacturing. The country's pharmaceutical and biotech sectors are focused on producing biosimilars, which are gaining traction due to their cost-effectiveness compared to original biologics. German companies are also leading efforts in the development of protein-based therapies for cancer, autoimmune diseases, and metabolic disorders. The integration of artificial intelligence and machine learning in drug development is expected to accelerate progress in Germany's bio-protein drug market.
India: India's bio-protein drug market is expanding rapidly, with a focus on affordable and accessible biologic treatments. The country's thriving pharmaceutical sector is producing a wide range of biosimilars, which are crucial for treating diseases like cancer, diabetes, and rheumatoid arthritis. India has become a manufacturing hub for bio-protein drugs, thanks to its low-cost production capabilities and increasing investments in biotechnology. The Indian government is also supporting the sector with initiatives to improve healthcare accessibility across the population.
Japan: Japan has a strong presence in the bio-protein drug market, with a focus on advanced biologics and monoclonal antibodies. The country's aging population is driving the demand for protein-based therapies, particularly in areas like cancer and diabetes treatment. Japanese companies are also exploring cutting-edge therapies, including gene and cell therapies, as part of the growing trend toward personalized medicine. Japan's efficient regulatory approval processes and high investment in healthcare are helping it maintain a competitive edge in the bio-protein drug sector.

Features of the Global Bio-Protein Drug Market

Market Size Estimates: Bio-protein drug market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Bio-protein drug market size by type, application, and region in terms of value ($B).
Regional Analysis: Bio-protein drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the bio-protein drug market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bio-protein drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the bio-protein drug market by type (monoclonal antibodies, therapeutic proteins, and vaccines), application (pharma and biotech companies, cros, and academics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Bio-Protein Drug Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Monoclonal Antibodies: Trends and Forecast (2019-2031)
4.4 Therapeutic Proteins: Trends and Forecast (2019-2031)
4.5 Vaccines: Trends and Forecast (2019-2031)

5. Global Bio-Protein Drug Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Pharma and Biotech Companies: Trends and Forecast (2019-2031)
5.4 CROs: Trends and Forecast (2019-2031)
5.5 Academics: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview
6.2 Global Bio-Protein Drug Market by Region

7. North American Bio-Protein Drug Market

7.1 Overview
7.2 North American Bio-Protein Drug Market by type
7.3 North American Bio-Protein Drug Market by application
7.4 United States Bio-Protein Drug Market
7.5 Mexican Bio-Protein Drug Market
7.6 Canadian Bio-Protein Drug Market

8. European Bio-Protein Drug Market

8.1 Overview
8.2 European Bio-Protein Drug Market by type
8.3 European Bio-Protein Drug Market by application
8.4 German Bio-Protein Drug Market
8.5 French Bio-Protein Drug Market
8.6 Spanish Bio-Protein Drug Market
8.7 Italian Bio-Protein Drug Market
8.8 United Kingdom Bio-Protein Drug Market

9. APAC Bio-Protein Drug Market

9.1 Overview
9.2 APAC Bio-Protein Drug Market by type
9.3 APAC Bio-Protein Drug Market by application
9.4 Japanese Bio-Protein Drug Market
9.5 Indian Bio-Protein Drug Market
9.6 Chinese Bio-Protein Drug Market
9.7 South Korean Bio-Protein Drug Market
9.8 Indonesian Bio-Protein Drug Market

10. ROW Bio-Protein Drug Market

10.1 Overview
10.2 ROW Bio-Protein Drug Market by type
10.3 ROW Bio-Protein Drug Market by application
10.4 Middle Eastern Bio-Protein Drug Market
10.5 South American Bio-Protein Drug Market
10.6 African Bio-Protein Drug Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunities by Type
- 12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Bio-Protein Drug Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis
13.2 Abbott Laboratories
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 Bayer AG
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 Eli Lilly and Company
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Amgen Inc.
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 Biocon Ltd.
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.7 Dr. Reddy'S Laboratories
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.8 Roche
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

简介目录图表

List of Figures

Figure 1.1: Trends and Forecast for the Global Bio-Protein Drug Market
Figure 2.1: Usage of Bio-Protein Drug Market
Figure 2.2: Classification of the Global Bio-Protein Drug Market
Figure 2.3: Supply Chain of the Global Bio-Protein Drug Market
Figure 3.1: Driver and Challenges of the Bio-Protein Drug Market
Figure 3.2: PESTLE Analysis
Figure 3.3: Patent Analysis
Figure 3.4: Regulatory Environment
Figure 4.1: Global Bio-Protein Drug Market by Type in 2019, 2024, and 2031
Figure 4.2: Trends of the Global Bio-Protein Drug Market ($B) by Type
Figure 4.3: Forecast for the Global Bio-Protein Drug Market ($B) by Type
Figure 4.4: Trends and Forecast for Monoclonal Antibodies in the Global Bio-Protein Drug Market (2019-2031)
Figure 4.5: Trends and Forecast for Therapeutic Proteins in the Global Bio-Protein Drug Market (2019-2031)
Figure 4.6: Trends and Forecast for Vaccines in the Global Bio-Protein Drug Market (2019-2031)
Figure 5.1: Global Bio-Protein Drug Market by Application in 2019, 2024, and 2031
Figure 5.2: Trends of the Global Bio-Protein Drug Market ($B) by Application
Figure 5.3: Forecast for the Global Bio-Protein Drug Market ($B) by Application
Figure 5.4: Trends and Forecast for Pharma and Biotech Companies in the Global Bio-Protein Drug Market (2019-2031)
Figure 5.5: Trends and Forecast for CROs in the Global Bio-Protein Drug Market (2019-2031)
Figure 5.6: Trends and Forecast for Academics in the Global Bio-Protein Drug Market (2019-2031)
Figure 6.1: Trends of the Global Bio-Protein Drug Market ($B) by Region (2019-2024)
Figure 6.2: Forecast for the Global Bio-Protein Drug Market ($B) by Region (2025-2031)
Figure 7.1: North American Bio-Protein Drug Market by type in 2019, 2024, and 2031
Figure 7.2: Trends of the North American Bio-Protein Drug Market ($B) by type (2019-2024)
Figure 7.3: Forecast for the North American Bio-Protein Drug Market ($B) by type (2025-2031)
Figure 7.4: North American Bio-Protein Drug Market by application in 2019, 2024, and 2031
Figure 7.5: Trends of the North American Bio-Protein Drug Market ($B) by application (2019-2024)
Figure 7.6: Forecast for the North American Bio-Protein Drug Market ($B) by application (2025-2031)
Figure 7.7: Trends and Forecast for the United States Bio-Protein Drug Market ($B) (2019-2031)
Figure 7.8: Trends and Forecast for the Mexican Bio-Protein Drug Market ($B) (2019-2031)
Figure 7.9: Trends and Forecast for the Canadian Bio-Protein Drug Market ($B) (2019-2031)
Figure 8.1: European Bio-Protein Drug Market by type in 2019, 2024, and 2031
Figure 8.2: Trends of the European Bio-Protein Drug Market ($B) by type (2019-2024)
Figure 8.3: Forecast for the European Bio-Protein Drug Market ($B) by type (2025-2031)
Figure 8.4: European Bio-Protein Drug Market by application in 2019, 2024, and 2031
Figure 8.5: Trends of the European Bio-Protein Drug Market ($B) by application (2019-2024)
Figure 8.6: Forecast for the European Bio-Protein Drug Market ($B) by application (2025-2031)
Figure 8.7: Trends and Forecast for the German Bio-Protein Drug Market ($B) (2019-2031)
Figure 8.8: Trends and Forecast for the French Bio-Protein Drug Market ($B) (2019-2031)
Figure 8.9: Trends and Forecast for the Spanish Bio-Protein Drug Market ($B) (2019-2031)
Figure 8.10: Trends and Forecast for the Italian Bio-Protein Drug Market ($B) (2019-2031)
Figure 8.11: Trends and Forecast for the United Kingdom Bio-Protein Drug Market ($B) (2019-2031)
Figure 9.1: APAC Bio-Protein Drug Market by type in 2019, 2024, and 2031
Figure 9.2: Trends of the APAC Bio-Protein Drug Market ($B) by type (2019-2024)
Figure 9.3: Forecast for the APAC Bio-Protein Drug Market ($B) by type (2025-2031)
Figure 9.4: APAC Bio-Protein Drug Market by application in 2019, 2024, and 2031
Figure 9.5: Trends of the APAC Bio-Protein Drug Market ($B) by application (2019-2024)
Figure 9.6: Forecast for the APAC Bio-Protein Drug Market ($B) by application (2025-2031)
Figure 9.7: Trends and Forecast for the Japanese Bio-Protein Drug Market ($B) (2019-2031)
Figure 9.8: Trends and Forecast for the Indian Bio-Protein Drug Market ($B) (2019-2031)
Figure 9.9: Trends and Forecast for the Chinese Bio-Protein Drug Market ($B) (2019-2031)
Figure 9.10: Trends and Forecast for the South Korean Bio-Protein Drug Market ($B) (2019-2031)
Figure 9.11: Trends and Forecast for the Indonesian Bio-Protein Drug Market ($B) (2019-2031)
Figure 10.1: ROW Bio-Protein Drug Market by type in 2019, 2024, and 2031
Figure 10.2: Trends of the ROW Bio-Protein Drug Market ($B) by type (2019-2024)
Figure 10.3: Forecast for the ROW Bio-Protein Drug Market ($B) by type (2025-2031)
Figure 10.4: ROW Bio-Protein Drug Market by application in 2019, 2024, and 2031
Figure 10.5: Trends of the ROW Bio-Protein Drug Market ($B) by application (2019-2024)
Figure 10.6: Forecast for the ROW Bio-Protein Drug Market ($B) by application (2025-2031)
Figure 10.7: Trends and Forecast for the Middle Eastern Bio-Protein Drug Market ($B) (2019-2031)
Figure 10.8: Trends and Forecast for the South American Bio-Protein Drug Market ($B) (2019-2031)
Figure 10.9: Trends and Forecast for the African Bio-Protein Drug Market ($B) (2019-2031)
Figure 11.1: Porter's Five Forces Analysis of the Global Bio-Protein Drug Market
Figure 11.2: Market Share (%) of Top Players in the Global Bio-Protein Drug Market (2024)
Figure 12.1: Growth Opportunities for the Global Bio-Protein Drug Market by Type
Figure 12.2: Growth Opportunities for the Global Bio-Protein Drug Market by Application
Figure 12.3: Growth Opportunities for the Global Bio-Protein Drug Market by Region
Figure 12.4: Emerging Trends in the Global Bio-Protein Drug Market

List of Tables

Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Bio-Protein Drug Market by Type and Application
Table 1.2: Attractiveness Analysis for the Bio-Protein Drug Market by Region
Table 1.3: Global Bio-Protein Drug Market Parameters and Attributes
Table 3.1: Trends of the Global Bio-Protein Drug Market (2019-2024)
Table 3.2: Forecast for the Global Bio-Protein Drug Market (2025-2031)
Table 4.1: Attractiveness Analysis for the Global Bio-Protein Drug Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Bio-Protein Drug Market (2019-2024)
Table 4.3: Market Size and CAGR of Various Type in the Global Bio-Protein Drug Market (2025-2031)
Table 4.4: Trends of Monoclonal Antibodies in the Global Bio-Protein Drug Market (2019-2024)
Table 4.5: Forecast for Monoclonal Antibodies in the Global Bio-Protein Drug Market (2025-2031)
Table 4.6: Trends of Therapeutic Proteins in the Global Bio-Protein Drug Market (2019-2024)
Table 4.7: Forecast for Therapeutic Proteins in the Global Bio-Protein Drug Market (2025-2031)
Table 4.8: Trends of Vaccines in the Global Bio-Protein Drug Market (2019-2024)
Table 4.9: Forecast for Vaccines in the Global Bio-Protein Drug Market (2025-2031)
Table 5.1: Attractiveness Analysis for the Global Bio-Protein Drug Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Bio-Protein Drug Market (2019-2024)
Table 5.3: Market Size and CAGR of Various Application in the Global Bio-Protein Drug Market (2025-2031)
Table 5.4: Trends of Pharma and Biotech Companies in the Global Bio-Protein Drug Market (2019-2024)
Table 5.5: Forecast for Pharma and Biotech Companies in the Global Bio-Protein Drug Market (2025-2031)
Table 5.6: Trends of CROs in the Global Bio-Protein Drug Market (2019-2024)
Table 5.7: Forecast for CROs in the Global Bio-Protein Drug Market (2025-2031)
Table 5.8: Trends of Academics in the Global Bio-Protein Drug Market (2019-2024)
Table 5.9: Forecast for Academics in the Global Bio-Protein Drug Market (2025-2031)
Table 6.1: Market Size and CAGR of Various Regions in the Global Bio-Protein Drug Market (2019-2024)
Table 6.2: Market Size and CAGR of Various Regions in the Global Bio-Protein Drug Market (2025-2031)
Table 7.1: Trends of the North American Bio-Protein Drug Market (2019-2024)
Table 7.2: Forecast for the North American Bio-Protein Drug Market (2025-2031)
Table 7.3: Market Size and CAGR of Various type in the North American Bio-Protein Drug Market (2019-2024)
Table 7.4: Market Size and CAGR of Various type in the North American Bio-Protein Drug Market (2025-2031)
Table 7.5: Market Size and CAGR of Various application in the North American Bio-Protein Drug Market (2019-2024)
Table 7.6: Market Size and CAGR of Various application in the North American Bio-Protein Drug Market (2025-2031)
Table 7.7: Trends and Forecast for the United States Bio-Protein Drug Market (2019-2031)
Table 7.8: Trends and Forecast for the Mexican Bio-Protein Drug Market (2019-2031)
Table 7.9: Trends and Forecast for the Canadian Bio-Protein Drug Market (2019-2031)
Table 8.1: Trends of the European Bio-Protein Drug Market (2019-2024)
Table 8.2: Forecast for the European Bio-Protein Drug Market (2025-2031)
Table 8.3: Market Size and CAGR of Various type in the European Bio-Protein Drug Market (2019-2024)
Table 8.4: Market Size and CAGR of Various type in the European Bio-Protein Drug Market (2025-2031)
Table 8.5: Market Size and CAGR of Various application in the European Bio-Protein Drug Market (2019-2024)
Table 8.6: Market Size and CAGR of Various application in the European Bio-Protein Drug Market (2025-2031)
Table 8.7: Trends and Forecast for the German Bio-Protein Drug Market (2019-2031)
Table 8.8: Trends and Forecast for the French Bio-Protein Drug Market (2019-2031)
Table 8.9: Trends and Forecast for the Spanish Bio-Protein Drug Market (2019-2031)
Table 8.10: Trends and Forecast for the Italian Bio-Protein Drug Market (2019-2031)
Table 8.11: Trends and Forecast for the United Kingdom Bio-Protein Drug Market (2019-2031)
Table 9.1: Trends of the APAC Bio-Protein Drug Market (2019-2024)
Table 9.2: Forecast for the APAC Bio-Protein Drug Market (2025-2031)
Table 9.3: Market Size and CAGR of Various type in the APAC Bio-Protein Drug Market (2019-2024)
Table 9.4: Market Size and CAGR of Various type in the APAC Bio-Protein Drug Market (2025-2031)
Table 9.5: Market Size and CAGR of Various application in the APAC Bio-Protein Drug Market (2019-2024)
Table 9.6: Market Size and CAGR of Various application in the APAC Bio-Protein Drug Market (2025-2031)
Table 9.7: Trends and Forecast for the Japanese Bio-Protein Drug Market (2019-2031)
Table 9.8: Trends and Forecast for the Indian Bio-Protein Drug Market (2019-2031)
Table 9.9: Trends and Forecast for the Chinese Bio-Protein Drug Market (2019-2031)
Table 9.10: Trends and Forecast for the South Korean Bio-Protein Drug Market (2019-2031)
Table 9.11: Trends and Forecast for the Indonesian Bio-Protein Drug Market (2019-2031)
Table 10.1: Trends of the ROW Bio-Protein Drug Market (2019-2024)
Table 10.2: Forecast for the ROW Bio-Protein Drug Market (2025-2031)
Table 10.3: Market Size and CAGR of Various type in the ROW Bio-Protein Drug Market (2019-2024)
Table 10.4: Market Size and CAGR of Various type in the ROW Bio-Protein Drug Market (2025-2031)
Table 10.5: Market Size and CAGR of Various application in the ROW Bio-Protein Drug Market (2019-2024)
Table 10.6: Market Size and CAGR of Various application in the ROW Bio-Protein Drug Market (2025-2031)
Table 10.7: Trends and Forecast for the Middle Eastern Bio-Protein Drug Market (2019-2031)
Table 10.8: Trends and Forecast for the South American Bio-Protein Drug Market (2019-2031)
Table 10.9: Trends and Forecast for the African Bio-Protein Drug Market (2019-2031)
Table 11.1: Product Mapping of Bio-Protein Drug Suppliers Based on Segments
Table 11.2: Operational Integration of Bio-Protein Drug Manufacturers
Table 11.3: Rankings of Suppliers Based on Bio-Protein Drug Revenue
Table 12.1: New Product Launches by Major Bio-Protein Drug Producers (2019-2024)
Table 12.2: Certification Acquired by Major Competitor in the Global Bio-Protein Drug Market

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

生物蛋白药物市场报告：趋势、预测与竞争分析（至2031年）

Bio-Protein Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

目录

第一章执行摘要

第二章 市场概览

第三章：市场趋势与预测分析

第四章 全球生物蛋白药物市场（按类型划分）

第五章 全球生物蛋白药物市场（依应用领域划分）

第六章 区域分析

第七章：北美生物蛋白药物市场

8. 欧洲生物蛋白製药市场

9. 亚太地区生物蛋白药物市场

第十章 世界其他地区（ROW）生物蛋白药物市场

第十一章 竞争分析

第十二章：机会与策略分析

第十三章：价值链中主要企业的概况

第十四章附录